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Background: Urinary symptoms and sexual dysfunction are the two most common complaints following prostate
radiotherapy. The impact of hypofractionated treatment on sexual function, irritative symptoms, and voiding symptoms
has not been determined within the same patient population. Here we present our institutional data on sexual
function, voiding function, irritative symptoms, and treatment response following SBRT.
Methods: This retrospective analysis includes 102 non-metastatic patients treated with SBRT at a single institution
between May 2008 and September 2014. The course of radiotherapy consisted of 36.25 Gy (range 35–40) over five daily
fractions. International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), and PSA were recorded
at baseline, 1, 3, 6, 9, 12, 18, 24, and 36 months after treatment.
Results: Median patient age was 72 years old with a median follow-up of 4.3 years. Pretreatment IPSS-I score was 5.21,
increasing to 6.97 (p < .001) after 1 month. The mean IPSS-I score returned close to baseline after 3 months to 5.86 and
decreased to below baseline after 2 years to 5.09. At 3 months, 9 months, and 2 years, 47.5, 76.2, and 91.1 % of patients
had reached IPSS-I resolution. The mean IPSS-O score prior to treatment was 5.31 and there was an increase in the
score to 6.45 (p = 0.344) at 1 month. The score remained close to baseline and decreased to 4.00 at 2 years and
significantly decreased to 3.74 (p = 0.035) at 3 years. 64.4, 82.1, and 96.0 % of patients had IPSS-O resolution by
3 months, 9 months, and 2 years. The mean SHIM score prior to treatment was 13.52 and continually decreased to
below baseline a year after treatment to 10.56 (p < .001). SHIM score began to improve at 18 months, but was still
significantly less than baseline at 12.12 (p = .01).
Conclusions: While an increase in AUA/IPSS score initially occurred, all patients resume normal activities immediately
following treatment and the AUA/IPSS symptoms improved from baseline. Irittative symptoms take longer to resolve
when compared to obstructive voiding symptoms in patients treated with SBRT. Three year PSA response, reported
toxicity, erectile function preservation, and urinary function improvement, shows favorable results.
Background
Stereotactic body radiation therapy (SBRT) allows for
precise high dose radiation with minimal exposure to ad-
jacent healthy tissue [1, 2]. Prostate cancer with an esti-
mated low α/β ratio of 1.0–1.7 may be more amenable to
a hypofractionated treatment approach via radiosurgical
techniques compared to standard fractionated external
beam techniques [3]. Given the reduced number of ses-
sions, hypofractionation may be more convenient, espe-
cially to patients with limited access to care. Numerous
studies have demonstrated the efficacy of several different
hypofractionation approaches including 2.5 Gy per frac-
tion to 70 Gy and 3.1 Gy per fraction to 62 Gy [4–13].
Recently, studies have demonstrated the efficacy of more
aggressive treatment regimens utilizing stereotactic body
radiation therapy (SBRT) techniques up to 10 Gy per frac-
tion to 50 Gy. However, while higher doses result in a
lower risk of biochemical failure, they also increase the
risk of bladder, rectal and small bowel toxicity [14–20].
There is limited data suggesting a superior treatment for
prostate cancer, and treatment is often based on patient
preference and a patient’s subsequent health-related qual-
ity of life [21].
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Lower urinary tract symptoms (LUTS) and sexual dys-
function are common following both surgery and radi-
ation therapy [22]. Obstructive voiding symptoms and
irritative symptoms are common LUTS and the preva-
lence could be as high as 30 % in men older than 70
[23]. Among men, the prevalence of LUTS has been
shown to increase with age. However, when comparing
prevalence of severe symptoms (an IPSS ranging between
20 and 35) there is no significant difference among various
younger age groups [24]. Initial reports suggest that the in-
cidence of irritative and obstructive symptoms resulting
from SBRT may be less than brachytherapy and compar-
able to external radiation therapy [20, 25, 26]. Erectile dys-
function is one of the most concerning toxicities after
radiotherapy. Conventionally fractionated external beam
radiation therapy (EBRT), brachytherapy, and SBRT all
have an affect on erectile function [27–29]. The dysfunc-
tion experienced by patients often returns to baseline with
time [30].
The goal of our study is to illustrate not only the effi-
cacy of using SBRT as a treatment modality for organ
confined prostate cancer, but also to demonstrate that
SBRT approach results in acceptable urinary and sexual
toxicity. Here we present our institutional data on sexual
function, voiding function, irritative symptoms, and treat-
ment response following SBRT.
Methods
Study design
This retrospective analysis includes prostate cancer pa-
tients treated with SBRT at a single institution on an IRB
approved protocol between May 2008 and September
2014. Eligible patients had biopsy-proven newly diag-
nosed, non-metastatic and untreated prostate cancer.
Study endpoints included early and late urinary toxicity,
sexual function questionnaire-based measures, and PSA
response. Prostate cancer risk stratification followed the
standard D’Amico risk stratification (low risk: PSA <10
and Gleason sum of 6 and clinical stage T1c–T2a, inter-
mediate risk: PSA 10–20 or Gleason sum of 7 or clinical
stage T2b, and high-risk: PSA >20 or Gleason sum 8–10
or clinical stage T2c/T3).
Treatment specifics
The CyberKnife (Accuray Inc., Sunnyvale CA) was used
to deliver fiducial-based image-guided SBRT. Four gold
fiducials were placed in the prostate via a trans-rectal or
trans-perineal approach using trans-rectal ultrasound
guidance, followed by a non-contrast CT scan in the su-
pine position. Anatomical contours of the prostate, sem-
inal vesicles, rectum, bladder, bladder neck, penile bulb,
and femoral heads were generated. The homogeneous
planning dose was prescribed to the planning target vol-
ume (PTV) that consisted of a volumetric expansion of
the prostate by 5 mm, reduced to 3 mm in the posterior
direction. The course of radiotherapy consisted of
36.25 Gy (range 35–40 Gy) over five daily fractions. Dose
was normalized to the 90 % isodose line in order for the
prescription dose to cover at least 95 % of the PTV. Gen-
erally speaking, dose volume histogram (DVH) goals for
the rectum were such that the V50 % <50 % (i.e., the vol-
ume receiving 50 % of the prescribed dose was <50 %),
V80 % <20 %, V90 % <10 % and V100 % <5 %. The bladder
DVH goals were V50 % <40 % and V100 % <10 %. The
femoral head DVH goal was V40 % <5 %. A short course
(median 4 months) of neoadjuvant and concurrent andro-
gen deprivation therapy (ADT) was allowed at the discre-
tion of the treating physician.
Follow-up and analysis
In general, PSAs were obtained at baseline, and pro-
spectively at 3-month post-treatment intervals during
the first 2 years and at 6-month intervals thereafter. The
PSA relapse definition used was the currently adopted
standard of care Phoenix definition (i.e., nadir +2). A benign
PSA bounce was called when PSA rose by > 0.2 ng/mL
above the post-treatment nadir and subsequently returned
to nadir levels or below.
Table 1 Baseline patient and treatment characteristics
Patients
(N = 101)
Age (y/o) Median 72 (47–88)
Age≤ 60 13.9 %
60 < Age≤ 70 51.5 %
Age > 70 34.6 %
Race White 55.6 %
Black 26.8 %
Other 17.6 %
Median prostate volume (cc) Median: 43 (14.0–170.7) cc




Baseline AUA score Median: 9.5
Mild (1–7): 41.6 %
Moderate (8–19): 41.6 %
Severe (20–35): 16.8 %
Baseline SHIM score Median: 15
Severe ED (1–7): 34.2 %
Moderate ED (8–11): 10.5 %
Mild-Moderate ED (12–16): 7.9 %
Mild ED (17–21): 21.1 %
Normal function (>21): 26.3 %
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Toxicities were recorded using the Common Termin-
ology Criteria for Adverse Events. American Urological
Association/International Prostate Symptom Score (AUA/
IPSS) and Sexual Health Inventory for Men (SHIM) were
recorded at baseline, 1, 3, 6, 9, 12, 18, 24, and 36 months
after treatment. The IPSS includes four questions related
to obstructive symptoms (incomplete emptying, inter-
mittency, weak stream, and straining) as well as three
questions related to irritative symptoms (frequency, ur-
gency and nocturia). For all the questions except the
nocturia question, the responses were grouped into
four clinically relevant categories (never, less than half
the time, half or more than half the time, and almost
always). For the nocturia question, the responses were
grouped into four clinically relevant categories (none, 1
time, 2 times and > 3 times). The IPSS obstructive sub-
score (IPSS-O) has been defined at the sum of the
scores for questions one, three, five, and six, while the
IPSS irritative subscore (IPSS-I) has been defined as
the sum of the scores for questions two, four, and seven
[31]. Overall IPSS-I scores range from 0 to 15 and
IPSS-O scores range from 0 to 20 with higher scores
indicating greater severity [22].
Wilcoxon Signed-Rank Test and chi-square analysis
were used to compare AUA/IPSS and SHIM scores to
baseline. Binary logistic regression was used in the
multivariate analysis to search for possible predicting
factors for IPSS-I or IPSS-O improvement. The endpoint
for this analysis was an IPSS-I/IPSS-O score at least one
point lower than baseline at 3 years post-SBRT. Baseline
characteristics including age, race, prostate volume, and
baseline ADT use were included as variables in the logis-
tic regression model. Time to IPSS, IPSS-I, and IPSS-O
resolution were determined using the Kaplan-Meier
method. Continuous variables were expressed using
sample medians and ranges.
Table 2 Changes in mean IPSS-total, IPSS-irritative, and IPSS-obstructive, from baseline following SBRT for prostate cancer
Pre 1 mo 3 mo 6 mo 9 mo 12 mo 18 mo 24 mo 36 mo
IPSS-Total
Mean 10.48 13.38 10.64 10.20 10.33 11.11 10.59 9.00 8.55
Mean difference 2.90 0.16 −0.28 −0.15 0.63 0.11 −1.48 −1.94
p-value < .001 1 1 1 1 1 1 .478
IPSS-irritative
Mean 5.21 6.97 5.86 5.45 5.51 5.77 5.41 5.09 4.81
Mean difference 1.76 0.65 0.24 0.30 0.56 0.20 −0.12 −0.40
p-value < .001 1 1 1 1 1 1 1
IPSS-obstructive
Mean 5.31 6.45 4.92 4.82 4.85 5.31 5.20 4.00 3.74
Mean difference 1.14 −0.39 −0.49 −0.46 0.00 −0.10 −1.31 −1.56
p-value 0.344 1 1 1 1 1 0.134 .035
Fig. 1 Median PSA for all patients before and after treatment
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Fig. 2 IPSS subscores over the 36 months of follow-up a Mean IPSS-total score for all patients. b Mean IPSS-Irritative score for all patients. c Mean
IPSS-obstructive score for all patients
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Results
From May 2008 to August 2013, 102 patients with a
median follow-up of 4.3 years were treated with SBRT.
The median patient age was 72 (47–88) years old with
55.6 % of the patients being white, and 26.8 % being
black (Table 1). The median prostate volume was 43 cc
(14–170.7) and 8.9 % of patients used androgen
deprivation therapy. 36.3 % of patients were low risk,
54.9 % of patients were intermediate risk, and 7.8 % of
patients were high risk based on the D’Amico classifica-
tion. 58.4 % of patients had moderate to severe lower
urinary tract symptoms (baseline AUA ≥ 8) and 73.7 %
of patients had some level of erectile dysfunction (base-
line SHIM ≤ 21) prior to treatment.
The median initial PSA was 5.8 ng/ml (Fig. 1). One
month after treatment, the median PSA decreased to
2.8 ng/ml. Six months after treatment the PSA was
1.4 ng/ml and then it continued to decrease to 1 ng/ml
after 1 year, 0.5 ng/ml after 2 years, and 0.3 ng/ml after
3 years. There were no biochemical failures and benign
PSA bounces occurred in 24 % with a median PSA
bounce of 0.6 ng/ml.
The mean AUA/IPSS score for all patients was 10.48 at
baseline, which corresponds with mild-to-moderate lower
urinary tract symptoms (Table 2) (Fig. 2a). After 1 month,
AUA/IPSS significantly increased to 13.38 (p < .001). The
scores returned to baseline by 3 months at 10.64, slightly
worsened at 1 year to 11.11, but then decreased below
baseline by 2 years with a mean score of 9.00. The median
time to IPSS resolution was 3 months with 56.4 % of pa-
tients returning to baseline by this time (Fig. 3a). By
9 months, 80.2 % of patients had reached IPSS resolution
and by 2 years 95 % of patients treated had resolved. Pre-
treatment IPSS-I score was 5.21, significantly increasing to
6.97 (p < .001) after 1 month (Fig. 2b). The mean IPSS-I
score returned close to baseline after 3 months to 5.86 and
decreased to below baseline after 2 years to 5.09. At
3 months, 47.5 % had reached IPSS-I resolution, at
9 months 76.2 % had reached resolution, and at 2 years
91.1 % of patients treated reached IPSS-I resolution
(Fig. 3b). The mean IPSS-O score prior to treatment was
5.31 and there was a non-statistically significant increase in
the score to 6.45 (p = 0.344) at 1 month (Fig. 2c). The score
remained close to baseline and decreased to 4.00 at 2 years
and significantly decreased to 3.74 (p = 0.035) at 3 years.
64.4 % of patients had IPSS-O resolution by 3 months,
82.1 % by 9 months, and 96.0 % by 2 years (Fig. 3c). Total
Fig. 3 IPSS resolution time a Total IPSS resolution time (return to
within two points of baseline score) b Total IPSS-irritative resolution
time (return to within one point of baseline score) c Total
IPSS-obstructive resolution time (return to within one point of
baseline score
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IPSS score and irritative score decreased after an initial
spike at 3 months, however all IPSS sub-scores had a minor
but not statistically significant increase at 12 months.
Analysis of SHIM score was limited to patients who
did not receive ADT (n = 92). The mean SHIM score
prior to treatment was 13.52, which was consistent with
mild to moderate erectile dysfunction (Table 3) (Fig. 4).
SHIM score significantly decreased after 1 month to
11.95 (p < .001) and continued to decrease below base-
line a year after treatment to 10.56 (p < .001). SHIM
score began to improve at 18 months, but was still sig-
nificantly less than baseline at 12.12 (p = .01). After
2 years, the mean SHIM score did not significantly differ
from baseline at 12.57 (p = 0.34), and continued to im-
prove after 3 years with a mean SHIM score of 13.06.
No patient reported RTOG Grade 3 or 4 urinary or rectal
toxicity following treatment. The incidence of Grade two
rectal toxicity was 3.0 % and the incidence of Grade two
urinary toxicity was 9.9 % during follow-up. Complete ob-
struction, persistent hematuria, or persistent rectal bleeding
was not observed in any patient during follow-up.
Discussion
Post-treatment PSA response, sexual function, and urinary
function all play an important role in the management of
prostate patients following SBRT. The use of PSA as a sur-
rogate endpoint is controversial. It has been suggested that
a short post treatment PSA doubling time of less than
3 months is a good indicator of prostate cancer mortality
after surgery or radiation therapy [32]. Similarly, an initial
post treatment 3-month decline of 20 to 40 % has been
shown to be a good indicator for overall survival [33]. This
is accordance with our data which showed a 64 % PSA de-
cline after 3-months. Since PSA expression is under hor-
monal control, androgen deprivation therapy can decrease
PSA independent to tumor response. Because so few pa-
tients used ADT, 8.9 %, it is unlikely that this had a major
effect on the data. Excluding ADT patients from the study
did not significantly decrease biochemical free survival
upon statistical analysis. Furthermore, our 3-year PSA
level of 0.3 ng/ml shows a similar result to previously pub-
lished data [19]. We expect the median PSA to further de-
crease with time, as Katz et al. reported a 0.1 ng/ml PSA
level after 48 and 60 months following a similar treatment
course [34]. Our data showed PSA bounces in 24 % of pa-
tients; this proved to be benign and transient as our 3-year
biochemical failure-free survival rate was 100 %. This con-
firmed the excellent long-term disease control of SBRT
previously demonstrated by Freeman et al. with a 5 year
biochemical disease free survival of 93 % [25], and Chen et
al. with a 99 % actuarial 2 year biochemical failure-free
survival rate [29]. While our 5-year results are encour-
aging, 10–15 years of data is needed before definitive
statements can be made on efficacy due to the long
natural history of the disease. Long-term results should
include data with 10+ years of results. The numbers
presented in this paper can’t statistically signify dosi-
metric correlations and anomalies. While we believe
doismetric parameters may effect short and long term
toxicity, follow-up times are not long enough to do this
statistical analysis.
Because the inclusion criteria for various modalities of
treatment can differ, comparing therapeutic strategies is
often imprecise [35], that being said, comparing the re-
sults of this study to other treatment modalities shows
favorable results. Radiation has been shown to result in
less obstructive and voiding issues when compared to
surgery [36]. IPSS resolution following brachytherapy
typically varies [27, 37], while IPSS scores, IPSS-I scores,
and IPSS-O scores have been shown to return to base-
line within 3 months following SBRT [20, 22, 38]. Our
IPSS and IPSS-I results were similar to SBRT data show-
ing a significant increase after 1 month and then no sig-
nificant change from baseline after 3 months, however,
IPSS-O scores did not significantly increase following
treatment and actually decreased below baseline after
3 months. IPSS and IPSS-I also decreased below baseline
after 2 years following the trend in previously published
data [20, 22, 38].
Urinary flare is an established complication in litera-
ture following both SBRT and brachytherapy [39, 40].
This consists of urinary frequency, dysuria, and/or ob-
structive voiding systems lasting approximately 1 year
after SBRT. This phenomenon is likely caused by blad-
der neck/urethral hyperemia in accordance with cystour-
ethritis. Our data showed urinary flare after 1 year for
total urinary symptoms and obstructive symptoms, and
after 18 months for irritative symptoms.
Radiation therapy causes less voiding symptoms when
compared to prostatectomy and this was demonstrated
by our results. The trade-off to this decrease has been
thought to be an increase in acute irritative symptoms
Table 3 Changes in mean SHIM score from baseline following SBRT for prostate cancer
Pre 1 mo 3 mo 6 mo 9 mo 12 mo 18 mo 24 mo 36 mo
SHIM
Mean 13.52 11.95 11.03 10.65 11.06 10.56 12.12 12.57 13.06
Mean difference −1.57 −2.49 −2.87 −2.46 −2.96 −1.40 −0.95 −0.46
p-value < .001 < .001 < .001 < .001 < .001 0.01 0.339 1
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following radiation and a decrease in irritative symptoms
within 1 year of prostatectomy [41, 42]. The decrease in
irritative symptoms following prostatectomy is thought
to be from relief of prostatic obstruction. Relief of pros-
tatic obstruction could also cause the reduction of symp-
toms in our data. SBRT is an ablative process and results
in a decrease in prostate size within 3 years of treatment
[43]; this decrease in size may result in improved urinary
symptoms.
Erectile dysfunction (ED), defined as a SHIM score
less than or equal to 21, has been reported to occur fol-
lowing both EBRT and prostatectomy. For either proced-
ure, Potosky et al. reported a 75 % ED rate after 5 years
[44], and Sanda et al. reported a 60 % ED rate after
2 years [28]. 76.3 % of our patients had some sort of
baseline erectile dysfunction prior to treatment. Sexual
potency, defined as a SHIM score less than or equal to
ten, was maintained by the majority with 78 % of pa-
tients maintaining sexual potency 2 years after SBRT.
Freeman et al. report that 82 % of patients who were
sexually potent before treatment maintained erectile
function post-treatment [16]. Furthermore, after 2 years,
our data showed no significant change from baseline
SHIM score and kept improving at 3 years. This was
similar to previously reported data which showed a de-
cline in SHIM after 1 year and then sexual function
stabilization shortly after [29, 30].
There were several limitations to this study. The use
of ADT results in reduction of prostate size, and could
explain improvement in urinary symptoms following
SBRT. This effect should be minimal as only 8.9 % of
the patient population studied used ADT with a median
of 4 months. The use of AUA and SHIM to assess func-
tion also narrows the scope of patient reported out-
comes and should be explored further. The retrospective
nature of this study carries biases. Carefully controlled
prospective trial should be conducted to further confirm
the effectiveness of SBRT in the treatment of prostate
cancer.
Conclusion
Prostate cancer patients treated with Cyberknife SBRT
exhibited minimal acute toxicity. 3 year PSA response,
reported toxicity, erectile function preservation, and
urinary function improvement compares favorably to
data presented following radical prostatectomy, brachy-
therapy, or conventional external beam radiation ther-
apy. While an increase in AUA/IPSS score initially
occurred, all patients resume normal activities immedi-
ately following treatment and the AUA/IPSS symptoms
improved from baseline. Irittative symptoms take lon-
ger to resolve when compared to obstructive voiding
symptoms in patients treated with SBRT.
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